Multiple system atrophy - cerebellar subtype (MSA-C) is a rare disease that causes areas deep in the brain, just above the spinal cord, to shrink (atrophy). MSA-C used to be known as olivopontocerebellar atrophy (OPCA).
MSA-C; Cerebellar multiple system atrophy; Olivopontocerebellar atrophy; OPCA; Olivopontocerebellar degeneration
MSA-C can be passed down through families (inherited form). It can also affect people without a known family history (sporadic form).
Researchers have identified certain genes that are involved in the inherited form of this condition.
The cause of MSA-C in people with the sporadic form is not known. The disease slowly gets worse (is progressive).
MSA-C is slightly more common in men than in women. The average age of onset is 54 years old.
Symptoms of MSA-C tend to start at a younger age in people with the inherited form. The main symptom is clumsiness (ataxia) that slowly gets worse. There may also be problems with balance, slurring of speech, and difficulty walking.
Other symptoms may include:
There is no specific treatment or cure for MSA-C. The aim is to treat the symptoms and prevent complications. This may include:
The following groups can provide resources and support for people with MSA-C:
MSA-C slowly gets worse, and there is no cure. The outlook is generally poor. But, it may be years before someone is very disabled.
Complications of MSA-C include:
Call your health care provider if you have any symptoms of MSA-C. You will need to be seen by a neurologist. This is a doctor who treats nervous system problems.
Published Date: June 23, 2020
Published By: Amit M. Shelat, DO, FACP, FAAN, Attending Neurologist and Assistant Professor of Clinical Neurology, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Ciolli L, Krismer F, Nicoletti F, Wenning GK. An update on the cerebellar subtype of multiple system atrophy. Cerebellum Ataxias. 2014;1-14. PMID: 26331038 pubmed.ncbi.nlm.nih.gov/26331038/.
Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670-676. PMID: 18725592 pubmed.ncbi.nlm.nih.gov/18725592/.
Jancovic J. Parkinson disease and other movement disorders. In: Daroff RB, Jankovic J, Mazziotta JC, Pomeroy SL, eds. Bradley's Neurology in Clinical Practice. 7th ed. Philadelphia, PA: Elsevier; 2016:chap 96.
Ma MJ. Biopsy pathology of neurodegenerative disorders in adults. In: Perry A, Brat DJ, eds. Practical Surgical Neuropathology: A Diagnostic Approach. 2nd ed. Philadelphia, PA: Elsevier, 2018:chap 27.
Walsh RR, Krismer F, Galpern WR, et al. Recommendations of the global multiple system atrophy research roadmap meeting. Neurology. 2018;90(2):74-82. PMID: 29237794 pubmed.ncbi.nlm.nih.gov/29237794/.